The Weight Loss Drug Competition Is Heating Up: These 2 Industry Leaders Just Filed Competing Drugs with the FDA. [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
One of these companies should lead this market, but both could be attractive buys. 10 stocks we like better than Novo Nordisk › The weight loss market has garnered plenty of headlines over the past two years. Yet, to date, and despite plenty of pipeline candidates, only two brands dominate this field. One of them is Wegovy, a medication marketed by Novo Nordisk (NYSE: NVO) , and the other is Zepbound, which was developed by Eli Lilly (NYSE: LLY) . These two are the undisputed leaders in this therapeutic area, and they could soon solidify their lead with important new approvals. Let's look into and determine what it all means for investors. Novo Nordisk's semaglutide, the active ingredient in Wegovy, mimics the action of the GLP-1 hormones, which play a role in regulating insulin and satiety. Wegovy is effective enough, but the company's CagriSema should be even more so. CagriSema is a dual agonist -- mimicking the actions of GLP-1 and another hormone called amylin, which also p
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk (NVO) Gets 9% Boost from Wegovy Pill OK [Yahoo! Finance]Yahoo! Finance
- Omeros: Why The Novo Nordisk Deal Is More Important Than FDA Approval (Rating Upgrade) [Seeking Alpha]Seeking Alpha
- Novo Nordisk just pulled off something nobody saw coming [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk: Oral Weight-Loss To The Rescue [Seeking Alpha]Seeking Alpha
- 3 Drug Stocks to Buy at a Discount [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 12/23/25 - Form 6-K
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- NVO's page on the SEC website